Cargando…

Induced Pluripotent Stem Cells Enable Disease Modeling and Drug Screening in Calreticulin del52 and ins5 Myeloproliferative Neoplasms

Mutations in the calreticulin (CALR) gene are seen in about 30% of essential thrombocythemia and primary myelofibrosis patients. To address the contribution of the human CALR mutants to the pathogenesis of myeloproliferative neoplasms (MPNs) in an endogenous context, we modeled the CALRdel52 and CAL...

Descripción completa

Detalles Bibliográficos
Autores principales:	Secardin, Lise, Gomez Limia, Cintia, da Silva-Benedito, Suzana, Lordier, Larissa, El-Khoury, Mira, Marty, Caroline, Ianotto, Jean-Christophe, Raslova, Hana, Constantinescu, Stefan N., Bonamino, Martín Hernán, Vainchenker, William, Monte-Mor, Barbara, Di Stefano, Antonio, Plo, Isabelle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8196125/ https://www.ncbi.nlm.nih.gov/pubmed/34131633 http://dx.doi.org/10.1097/HS9.0000000000000593

Ejemplares similares

Calreticulin del52 and ins5 knock-in mice recapitulate different myeloproliferative phenotypes observed in patients with MPN
por: Benlabiod, Camélia, et al.
Publicado: (2020)

Secreted mutant calreticulins as rogue cytokines in myeloproliferative neoplasms
por: Pecquet, Christian, et al.
Publicado: (2023)

JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders
por: Vainchenker, William, et al.
Publicado: (2018)

Calreticulin Mutations in Myeloproliferative Neoplasms
por: Lavi, Noa
Publicado: (2014)

Mutant Calreticulin in the Myeloproliferative Neoplasms
por: Prins, Daniel, et al.
Publicado: (2020)

Calreticulin Exon 9 Mutations in Myeloproliferative Neoplasms
por: Ha, Jung-Sook, et al.
Publicado: (2015)

Heterozygous and Homozygous JAK2(V617F) States Modeled by Induced Pluripotent Stem Cells from Myeloproliferative Neoplasm Patients
por: Saliba, Joseph, et al.
Publicado: (2013)

Role of Rho-GTPases in megakaryopoiesis
por: Vainchenker, William, et al.
Publicado: (2021)

Inferring the initiation and development of myeloproliferative neoplasms
por: Hermange, Gurvan, et al.
Publicado: (2022)

Functional Consequences of Mutations in Myeloproliferative Neoplasms
por: Constantinescu, Stefan N., et al.
Publicado: (2021)

P53 activation inhibits all types of hematopoietic progenitors and all stages of megakaryopoiesis
por: Mahfoudhi, Emna, et al.
Publicado: (2016)

Calreticulin Mutations in Myeloproliferative Neoplasms: Comparison of Three Diagnostic Methods
por: Park, Ji-Hye, et al.
Publicado: (2015)

The Mutation Profile of Calreticulin in Patients with Myeloproliferative Neoplasms and Acute Leukemia
por: Wang, Jingyi, et al.
Publicado: (2016)

A novel assay to detect calreticulin mutations in myeloproliferative neoplasms
por: Rosso, Valentina, et al.
Publicado: (2016)

Mechanism underlying the development of myeloproliferative neoplasms through mutant calreticulin
por: Edahiro, Yoko, et al.
Publicado: (2020)

Calreticulin Ins5 and Del52 mutations impair unfolded protein and oxidative stress responses in K562 cells expressing CALR mutants
por: Salati, Simona, et al.
Publicado: (2019)

Somatic mutations of calreticulin in a Brazilian cohort of patients with myeloproliferative neoplasms
por: Machado-Neto, João Agostinho, et al.
Publicado: (2015)

Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value
por: Vannucchi, A M, et al.
Publicado: (2014)

The Expression of Myeloproliferative Neoplasm-Associated Calreticulin Variants Depends on the Functionality of ER-Associated Degradation
por: Mansier, Olivier, et al.
Publicado: (2019)

Production and Characterization of Peptide Antibodies to the C-Terminal of Frameshifted Calreticulin Associated with Myeloproliferative Diseases
por: Mughal, Farah Perveen, et al.
Publicado: (2022)

New pathogenic mechanisms induced by germline erythropoietin receptor mutations in primary erythrocytosis
por: Pasquier, Florence, et al.
Publicado: (2018)

Low neutrophil alkaline phosphatase score is a new aspect of calreticulin-mutated myeloproliferative neoplasms
por: Kondo, Toshinori, et al.
Publicado: (2016)

P1001: MODULATION OF MUTANT CALRETICULIN-DRIVEN ONCOGENESIS IN MYELOPROLIFERATIVE NEOPLASMS BY CLASSICAL HLA GENES
por: Shivarov, Velizar, et al.
Publicado: (2023)

Recent advances in therapies for primary myelofibrosis
por: Vainchenker, William, et al.
Publicado: (2023)

Platelet function studies in myeloproliferative neoplasms patients with Calreticulin or JAK2(V617F) mutation
por: Guy, Alexandre, et al.
Publicado: (2023)

Recent advances in understanding myelofibrosis and essential thrombocythemia
por: Vainchenker, William, et al.
Publicado: (2016)

Thrombocytopenia induced by the histone deacetylase inhibitor abexinostat involves p53-dependent and -independent mechanisms
por: Ali, A, et al.
Publicado: (2013)

Surface-exposed and soluble calreticulin: conflicting biomarkers for cancer prognosis
por: Kepp, Oliver, et al.
Publicado: (2020)

Calreticulin and the Heart
por: Groenendyk, Jody, et al.
Publicado: (2022)

Rapid, low cost and sensitive detection of Calreticulin mutations by a PCR based amplicon length differentiation assay for diagnosis of myeloproliferative neoplasms
por: Trung, Ngo Tat, et al.
Publicado: (2019)

Calreticulin Immunohistochemistry in Myeloproliferative Neoplasms - Evolution of a New Cost-Effective Diagnostic Tool: A Retrospective Study with Histological and Molecular Correlation
por: Roy, Sanjeet, et al.
Publicado: (2022)

P988: MUTANT CALRETICULIN AND JAK2V617F DRIVER MUTATIONS INDUCE DISTINCT MITOTIC DEFECTS IN MYELOPROLIFERATIVE NEOPLASMS
por: Holl, Kristin, et al.
Publicado: (2023)

An Efficient Electroporation Protocol for the Genetic Modification of Mammalian Cells
por: Chicaybam, Leonardo, et al.
Publicado: (2017)

Evaluation of vascular events in patients with myeloproliferative syndromes and mutations of either the januskinase-2 or calreticulin gene at the university hospital Krems from 2008 to 2015
por: Hintermair, Sarah, et al.
Publicado: (2018)

Calreticulin: Challenges Posed by the Intrinsically Disordered Nature of Calreticulin to the Study of Its Function
por: Varricchio, Lilian, et al.
Publicado: (2017)

Primary hematopoietic cells from DBA patients with mutations in RPL11 and RPS19 genes exhibit distinct erythroid phenotype in vitro
por: Moniz, H, et al.
Publicado: (2012)

Comparison of Clinical and Hematological Parameters of Janus Kinase 2, Calreticulin or Myeloproliferative Leukemia Virus Oncogene Mutant Essential Thrombocythemia and Triple-Negative Essential Thrombocythemia
por: Yıldız, Jale, et al.
Publicado: (2022)

Therapeutic cancer vaccination against mutant calreticulin in myeloproliferative neoplasms induces expansion of specific T cells in the periphery but specific T cells fail to enrich in the bone marrow
por: Holmström, Morten Orebo, et al.
Publicado: (2023)

Genetic Alterations of the Thrombopoietin/MPL/JAK2 Axis Impacting Megakaryopoiesis
por: Plo, Isabelle, et al.
Publicado: (2017)

Identification of MPL R102P Mutation in Hereditary Thrombocytosis
por: Bellanné-Chantelot, Christine, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_fqq73dki5oesqj03qoj0lvl6r7